Characteristics and Long-Term Outcome of Patients with Systemic Immunoglobulin Light-Chain Amyloidosis

Publisher： Karger

E-ISSN： 1421-9662|133|4|336-346

ISSN： 0001-5792

Source： Acta Haematologica, Vol.133, Iss.4, 2014-12, pp. : 336-346

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : E60-E65

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 97, Iss. 4, 2016-10 ,pp. : 342-347

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 6, 2015-09 ,pp. : 804-813

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy

By  

Acta Haematologica, Vol. 135, Iss. 3, 2016-01 ,pp. : 172-190

Karger

Access to resources Recommend Favorite

A Patient with Multiple Myeloma, Amyloidosis and Light-Chain Deposition Disease in Kidneys with a Long Survival

By  

Acta Haematologica, Vol. 101, Iss. 4, 1999-07 ,pp. : 202-205

Karger

Access to resources Recommend Favorite